ID   CHLA-32
AC   CVCL_M151
SY   CHLA32
DR   cancercelllines; CVCL_M151
DR   Cell_Model_Passport; SIDM01536
DR   Cosmic; 2228218
DR   DepMap; ACH-001032
DR   GEO; GSM1676355
DR   GEO; GSM1701685
DR   Wikidata; Q54812497
RX   PubMed=15289350;
RX   PubMed=24312454;
RX   PubMed=25010205;
RX   PubMed=26351324;
WW   Provider; CCR; -; https://www.cccells.org/PDF_Files/Ewings/CHLA-32%20Cell%20Line%20Data%20Sheet.pdf
WW   Provider; CCR; -; https://www.cccells.org/tables/Ewings.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 26 hours (PubMed=24312454).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=25010205; DepMap=ACH-001032).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Transcriptomics; RNAseq.
ST   Source(s): COG; PubMed=24312454; PubMed=25010205
ST   Amelogenin: X
ST   CSF1PO: 10,11 (PubMed=24312454)
ST   CSF1PO: 11 (COG; PubMed=25010205)
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 18,19 (PubMed=24312454)
ST   D18S51: 19 (COG; PubMed=25010205)
ST   D19S433: 13,15
ST   D21S11: 28,31
ST   D2S1338: 24
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 8,9
ST   D8S1179: 13,15
ST   FGA: 24
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   8Y6M
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-04-25; Version: 22
//
RX   PubMed=15289350; DOI=10.1158/0008-5472.CAN-04-0377;
RA   Batra S., Reynolds C.P., Maurer B.J.;
RT   "Fenretinide cytotoxicity for Ewing's sarcoma and primitive
RT   neuroectodermal tumor cell lines is decreased by hypoxia and
RT   synergistically enhanced by ceramide modulators.";
RL   Cancer Res. 64:5415-5424(2004).
//
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060; PMCID=PMC3846563;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:e80060.1-e80060.10(2013).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475; PMCID=PMC4091782;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T.A., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:e1004475.1-e1004475.13(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476;
RA   Teicher B.A., Polley E.C., Kunkel M.W., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//